Testing vamorolone for Becker muscular dystrophy
Vamorolone trial in Becker muscular dystrophy
This study is looking at how a new medication called vamorolone can help improve muscle strength and health for people with Becker muscular dystrophy, offering a safer option than current treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Reveragen Biopharma, INC. NIH-funded |
| Lab location | 1 site (Rockville, United States) |
| Project ID | NIH-10491103 on NIH RePORTER |
What this research studies
This research investigates the use of vamorolone, a new medication, to treat Becker muscular dystrophy, a condition caused by a partial loss of the dystrophin protein in muscles. The study aims to assess how vamorolone can improve muscle function and overall health in patients with this condition. By focusing on a population that has been largely overlooked in drug development, the research seeks to provide a safer alternative to current treatments like corticosteroids, which have significant side effects. Patients will be monitored for changes in muscle strength and function throughout the trial.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Becker muscular dystrophy who are experiencing muscle weakness.
Not a fit: Patients with Duchenne muscular dystrophy or those without a diagnosis of Becker muscular dystrophy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that improves muscle function and quality of life for patients with Becker muscular dystrophy.
How similar studies have performed: While there has been significant progress in treatments for Duchenne muscular dystrophy, research specifically targeting Becker muscular dystrophy is less common, making this approach relatively novel.
Where this research is happening
Rockville, United States
- Reveragen Biopharma, INC. — Rockville, United States (Active)
Researchers
- Principal investigator: Hoffman, Eric P. — Reveragen Biopharma, INC.
- Study coordinator: Hoffman, Eric P.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.